Today's Date: June 6, 2023
University of Phoenix Collaborates with Ardent Health Services to Provide Education and Tuition Reimbursement for Employees   •   Roth Staffing Named to ClearlyRated's Inaugural Best Staffing Firms for Women List   •   PrideStaff Named to ClearlyRated's Best Staffing Firms for Women List   •   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of SentinelOne, Inc.   •   Devonian Announces Closing of a Private Placement of $1.2 Million   •   Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Funko, Inc. (FNKO)   •   ACC Honors Companies for Efforts to Advance Sustainability with its 2023 Sustainability Leadership Awards   •   AVOCADO TO DONATE 1% OF REVENUE TO WOMEN'S EARTH ALLIANCE   •   Coalition For Change (C4C) Releases Report to President Biden on EEOC's Flawed EEO Complaint System   •   RK Pharma to receive up to USD 200 million investment from PAG   •   Coach Nick Saban, Ms. Terry Saban surprise children with award-winning My Special Aflac Duck®   •   WCM Champions of Change Close the Market   •   PRIMO Partners Honored with Distinguished 2023 MVP Award from Multi-Unit Franchisee Magazine   •   Antibiotic Overuse a Slippery Slope for STI Prevention, says AHF   •   Lost Money in Tingo Group, Inc.?   •   Maine Public Utilities Commission Unanimously Approve Central Maine Power Multi-year Rate Plan   •   Morgan Stanley Global M&A Chair Robert Kindler to Join Paul, Weiss   •   PrideStaff Financial Named to ClearlyRated's Best Staffing Firms for Women List   •   With New Recycling Center Fully Operational, EGGER Now Manufactures Products With Post-Consumer Recycled Wood   •   S CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against SentinelOne, Inc.
Bookmark and Share

Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)

TOKYO , March 27 /Businesswire/ - Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health University and Keio University presented at the 22nd Japanese Society for Regenerative Medicine Annual Conference (Kyoto, Japan, March 23-25, 2023) that iPS cell-derived corneal endothelial cell substitute ("CLS001") was transplanted to the first patient (First In Human*, "FIH Study").

The details of presentation information are as follows;

Title: iPS-derived Cornea Endothelial Substitutes for Corneal Regeneration

Lecture Number: SY-02-2

Date & Time: Thursday, March 23, 2023, 8:30-10:30 a.m.

This FIH study (Study title: Exploratory Clinical Study to Examine Safety and Efficacy of iPS Cell-Derived Corneal Endothelial Cell Substitutes for Bullous Keratopathy, jRCT study protocol number: jRCTa031210199) was conducted at the Department of Ophthalmology, Keio University Hospital to evaluate the safety and efficacy of CLS001 transplantation in patients with regrafted cases of bullous keratopathy.

In the presentation, Prof. Shimmura reported that the safety was confirmed since no adverse event has been observed for 3 months after the CLS001 transplantation at the review of the Independent Data Monitoring Committee held in January 2023. In addition, in terms of the efficacy, he also reported that the visual acuity, central corneal thickness, and minimal corneal thickness has tended to be improved so far.

Cellusion is challenging to solve the global cornea shortage issue by developing CLS001. With the progress of the FIH study, we will accelerate the preparation of the Cellusion sponsored clinical trial.

*First-in-human (FIH) studies: Clinical studies or Phase I clinical trials in which a drug is administered to humans for the first time after its safety and efficacy have been confirmed in animal studies.

[About Bullous Keratopathy]

Bullous keratopathy is a disease that causes blistering of the cornea and visual impairment due to clouding caused by a decrease in corneal endothelial cells, which regulate the proper amount of water in the cornea, due to cataracts or other eye surgery or hereditary factors. The disease is progressive and can lead to blindness if left untreated. Currently, the only treatment available for this disease is a corneal transplant that replaces normally functioning corneal endothelial cells. However, like other organ transplants, corneal transplants are facing a serious shortage of donors. It is estimated that there are more than 10,000 patients in Japan, and a global survey conducted in 2013 reported that there are some 13 million people worldwide on the waiting list for corneal transplants.

[About CLS001]

In spite of the fact that more than 13 million waiting patients for potential blinding diseases such as Bullous Keratopathy, which can only be prevented by corneal transplantation, only about 180,000 corneal transplants are performed annually worldwide. The reason for such a large medical supply-demand gap generated is because current treatments require donor corneas, skilled corneal transplant ophthalmologists, and Eye Banks.

Cellusion is developing CLS001, CECSi cells for Corneal Endothelial regeneration to cure Bullous Keratopathy which is applied to more than half of all cases of corneal transplantation. CLS001 is expected to replace the current supply limitations by combining "CECSi Cells made from iPS cells with excellent proliferative properties" and "a simple injection cell delivery procedure without needs of human expertise."

[About Cellusion]

Cellusion is a regenerative medicine startup born from the Department of Ophthalmology, Keio University School of Medicine in 2015. Cellusion aims to contribute to the improvement of health and well-being around the world by solving unmet medical needs in medicine with its cutting-edge cell therapy technologies, including a unique differentiation induction method from iPS cells to CECSi endothelial cells. Cellusion’s mission is to give the worldwide community a clear vision of the future with the cellular technology breakthrough.

Company: Cellusion Inc.

CEO: Shin Hatou, M.D., Ph.D.

Headquarters: 8-6 Nihonbashi-Kobuna, Chuo, Tokyo 103-0024, JAPAN

Founded: January 2015


For further information: please ask us through the contact form on our website.

STORY TAGS: Biotechnology, Health, Pharmaceutical, Surgery, Professional Services, Optical, Stem Cells, University, Research, Education, Start-Up, Hospitals, Science, Clinical Trials, Conference, Product/Service, Japan, Asia Pacific,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News